Tag: $Boston Scientific

Boston Scientific (BSX) said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices, but the company cut its adjusted earnings growth projection for the year.

Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as pulmonary embolism and stroke.